-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 20, Biogen announced that it would reduce the wholesale acquisition cost of the new Alzheimer’s disease drug Aduhelmd (100mg/ml specification) by approximately 50% from January 1, 2022
Bojian CEO Michel Vounatsos said that in the past few months, we have been listening to feedback from various stakeholders, and today we have taken an important step to improve the accessibility of Aduhelmd
Bojian's move is aimed at reducing the out-of-pocket expenses of AD patients using Aduhelmd and reducing the burden on the US healthcare system
Bojian's lowering of Aduhelmd's price has a lot to do with its poorer-than-expected sales performance after listing
On December 17, the European Medicines Agency (EMA) Committee for Medicines for Human Use (CHMP) also held a negative opinion on the marketing right application (MAA) of Aduhelm (aducanumab) for the treatment of early Alzheimer's disease